nach oben

World Journal of Urology

Erschienen in:

01.04.2011 | Original Article

Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia

verfasst von: Yasuhito Funahashi, Ryohei Hattori, Yoshihisa Matsukawa, Tomonori Komatsu, Naoto Sassa, Momokazu Gotoh

Erschienen in: World Journal of Urology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The efficacy of a loading dose of α₁-adrenoreceptor antagonist for patients with benign prostate hyperplasia who did not improve at a low dose has not been determined. We performed a prospective study to estimate the efficacy of incremental naftopidil administration.

Methods

The efficacy of naftopidil was examined based on changes in the International Prostate Symptom Score (IPSS). We defined a “responder” as a patient who improved by ≥5 points in IPSS total score. All patients were administered naftopidil at 50 mg/day for 12 weeks, and nonresponders at 50 mg/day were increased to 75 mg/day. Efficacy was finally evaluated after an additional 12 weeks of administration at 75 mg/day.

Results

Among 122 patients whose data could be analyzed, the efficacy rate after administration at 50 mg/day was 52.5%. In all IPSS items except urgency score, the responders had significantly higher (poorer) values than nonresponders before the start of treatment. Of 40 patients whose dose was increased to 75 mg/day and whose data could be analyzed, prostate volume in the responder group (9 patients) was significantly smaller than that in the nonresponder group (31 patients). Multivariate analysis showed that patients with improved IPSS total score, voiding symptoms, urgency, and weak stream after administration of 50 mg/day naftopidil were more likely to improve after a dose increase.

Conclusions

A dose increment of naftopidil to 75 mg/day may be useful in patients with BPH who did not improve at 50 mg/day.

Gonzalez RR, Kaplan SA (2006) First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment? World J Urol 24:360–366PubMedCrossRef

AUA guideline on management of benign prostatic hyperplasia (2003) Chapter 1: diagnosis and treatment recommendations. J Urol 170:530–547CrossRef

Oh-oka H (2009) Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose–comparison between 75 and 50 mg. Urol Int 82:136–142PubMedCrossRef

Ikemoto I, Kiyota H, Ohishi Y et al (2003) Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int J Urol 10:587–594PubMedCrossRef

Gotoh M, Kamihira O, Kinukawa T et al (2005) Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 96:581–586PubMedCrossRef

Nishino Y, Masue T, Miwa K et al (2006) Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 97:747–751 (discussion 751)PubMedCrossRef

Takahashi S, Tajima A, Matsushima H et al (2006) Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol 13:15–20PubMedCrossRef

Masumori N, Hashimoto J, Itoh N et al (2007) Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand J Urol Nephrol 41:422–429PubMedCrossRef

Yokoyama T, Kumon H, Nasu Y et al (2006) Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. Int J Urol 13:932–938PubMedCrossRef

10.

Oh-oka H (2008) Effect of naftopidil on nocturia after failure of tamsulosin. Urology 72:1051–1055PubMedCrossRef

11.

Tsujihata M, Yoshimura K, Kojima Y et al (2009) The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance. Hinyokika Kiyo 55:181–186PubMed

12.

Ukimura O, Kanazawa M, Fujihara A et al (2008) Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. Int J Urol 15:1049–1054PubMedCrossRef

13.

Ishizaka K, Machida T, Tanaka M et al (2007) Clinical efficacy of naftopidil in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia—a clinical comparison of naftopidil with tamsulosin hydrochloride. Jpn J Urol Surg 20:881–889

14.

Sountoulides P, van Dijk MM, Wijkstra H et al. (2009) Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol, in press

15.

Matsuo S, Suzuki T, Minagawa S et al (2004) Clinical efficacy of the loading dosage to naftopidil 75 mg for urinary disturbance associated with BPH. Jpn J Urol Surg 17:393–398

16.

Kobayashi M, Nukui A, Ochi M et al (2006) Clinical efficacy of loading dosage of Naftopidil for lower urinary tract symptoms in men with benign prostate hyperplasia—Who will benefit from the loading dosage? Jpn J Urol Surg 19:137–144

17.

Masuda M, Hirokawa M, Furuhata A et al (2007) Clinical study of the loading dosage escalation to naftopidil 75 mg on urinary disturbance associated with benign prostate hyperplasia. Jpn J Urol Surg 20:773–778

18.

Chon JK, Borkowski A, Partin AW et al (1999) Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161:2002–2008PubMedCrossRef

19.

Kobayashi S, Tomiyama Y, Hoyano Y et al (2009) Mechanical function and gene expression of α1-adrenoceptor subtypes in dog intravesical ureter. Urology 74:458–462PubMedCrossRef

20.

Chen Q, Takahashi S, Zhong S et al (2005) Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor. J Urol 174:370–374PubMedCrossRef

21.

Ishihama H, Momota Y, Yanase H et al (2006) Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol 175:358–364PubMedCrossRef

22.

Yokoyama O, Yusup A, Oyama N et al (2006) Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn 25:461–467PubMedCrossRef

23.

Ishizaka K, Machida T, Tanaka M et al (2009) Clinical efficacy of naftopidil on lower urinary tract symptoms after radical prostatectomy. Int J Urol 16:299–302PubMedCrossRef

Titel: Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia
verfasst von: Yasuhito Funahashi
Ryohei Hattori
Yoshihisa Matsukawa
Tomonori Komatsu
Naoto Sassa
Momokazu Gotoh
Publikationsdatum: 01.04.2011
Verlag: Springer-Verlag
Erschienen in: World Journal of Urology / Ausgabe 2/2011
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-010-0528-4

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia